Mn Services Vermogensbeheer B.V. Increases Stake in Celgene Corporation (CELG)
Mn Services Vermogensbeheer B.V. grew its holdings in Celgene Corporation (NASDAQ:CELG) by 520.9% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 128,374 shares of the biopharmaceutical company’s stock after buying an additional 107,700 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Celgene Corporation were worth $16,672,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Celgene Corporation in the first quarter valued at about $118,000. Oakworth Capital Inc. increased its stake in shares of Celgene Corporation by 60.9% during the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after acquiring an additional 412 shares during the period. Acropolis Investment Management LLC acquired a new position in shares of Celgene Corporation during the second quarter worth about $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 380 shares during the period. Finally, Schmidt P J Investment Management Inc. acquired a new position in shares of Celgene Corporation during the first quarter worth about $201,000. 79.33% of the stock is owned by institutional investors and hedge funds.
Shares of Celgene Corporation (NASDAQ:CELG) traded up 2.14% during trading on Friday, hitting $145.82. 4,324,637 shares of the company traded hands. The firm has a 50 day moving average price of $135.45 and a 200-day moving average price of $127.81. Celgene Corporation has a one year low of $96.93 and a one year high of $146.00. The stock has a market cap of $114.08 billion, a price-to-earnings ratio of 45.16 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same period last year, the firm posted $1.44 earnings per share. Analysts predict that Celgene Corporation will post $7.32 EPS for the current year.
In other news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the completion of the transaction, the director now directly owns 76,301 shares in the company, valued at $10,264,010.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 46,233 shares of company stock worth $6,268,259. 0.95% of the stock is currently owned by insiders.
CELG has been the topic of a number of recent analyst reports. Canaccord Genuity set a $156.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Tuesday, June 6th. Cann reiterated a “buy” rating on shares of Celgene Corporation in a research note on Wednesday, June 7th. Oppenheimer Holdings, Inc. set a $148.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, June 8th. BidaskClub upgraded shares of Celgene Corporation from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 14th. Finally, Leerink Swann upgraded shares of Celgene Corporation from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $94.42 to $150.00 in a research note on Friday, June 16th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $150.31.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.